GK921, a transglutaminase inhibitor, strengthens the antitumor effect of cisplatin on pancreatic cancer cells by inhibiting epithelial-to-mesenchymal transition
Authors:
- 30 October 2023
- journal article
- research article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1870 (2) , 166925
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Role of tissue transglutaminase-2 (TG2)-mediated aminylation in biological processesAmino Acids, 2016
- Epithelial‐to‐Mesenchymal Transition in Paclitaxel‐Resistant Ovarian Cancer Cells Is Downregulated by LuteolinJournal of Cellular Physiology, 2016
- Silencing of TGM2 reverses epithelial to mesenchymal transition and modulates the chemosensitivity of breast cancer to docetaxelExperimental and Therapeutic Medicine, 2015
- Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathwayCell Death & Disease, 2015
- ZEB1‐associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostatEMBO Molecular Medicine, 2015
- Transglutaminase-2 is Involved in Cell Apoptosis of Osteosarcoma Cell Line U2OS Under Hypoxia ConditionCell Biochemistry and Biophysics, 2015
- Tissue transglutaminase expression promotes castration-resistant phenotype and transcriptional repression of androgen receptorEuropean Journal of Cancer, 2014
- TGM2 inhibition attenuates ID1 expression in CD44-high glioma-initiating cellsNeuro-Oncology, 2013
- Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancerBreast Cancer Research, 2013
- Polymorphism of transglutaminase 2: unusually low frequency of genomic variants with deficient functionsAmino Acids, 2011